Cystic Fibrosis Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):–
The Global Cystic Fibrosis Market reached US$ 10.96 billion in 2023 and is expected to reach US$ 26.58 billion by 2031, growing at a CAGR of 11.8% during the forecast period 2024-2031.
List of the Key Players in the Cystic Fibrosis Market:
Novartis AG, Vertex Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Gilead sciences, Alcresta Therapeutics Inc, Merck Co. Inc, Pfizer Inc, Genentech, Chiesi Pharmaceuticals B.V.
Industry Development:
In May 2024, Arcturus Therapeutics Holdings Inc., a global biopharmaceutical company specializing in infectious disease vaccines and treatments for rare liver and respiratory diseases, presented Phase 1 results for ARCT-032, an inhaled investigational mRNA therapeutic. The data, including interim findings from a Phase 1b study in cystic fibrosis (CF) patients, was shared at the 47th European Cystic Fibrosis Conference.
In July 2024, Sionna Therapeutics entered a licensing agreement with AbbVie, granting the pharmaceutical giant exclusive global rights to develop and commercialize multiple clinical-stage compounds, including two currently in Phase 2 trials. This collaboration aims to enhance CF treatment by targeting the CFTR protein, potentially transforming care for cystic fibrosis patients.
Growth Forecast Projected:
The Global Cystic Fibrosis Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Segment Covered in the Cystic Fibrosis Market:
By Drug Class: CFTR Modulators, Antibiotics, Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, Others
By Route of Administration: Oral, Inhaled, Parenteral
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Regional Analysis for Cystic Fibrosis Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East Africa)
Benefits of the Report:
➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.
➡ Top-down and bottom-up approach for regional analysis
➡ Porter’s five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants substitutes and competition amongst the key market players.
➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
